Key regions: France, India, United Kingdom, South Korea, Japan
The Multiple Sclerosis Drugs market in Croatia has seen a steady growth in recent years, driven by various factors such as customer preferences, local special circumstances, and underlying macroeconomic factors.
Customer preferences: Patients in Croatia suffering from Multiple Sclerosis (MS) prefer disease-modifying therapies that can slow down the progression of the disease and improve their quality of life. They prefer oral medications over injectables due to convenience and ease of use. Moreover, they also prefer drugs that have fewer side effects and are cost-effective.
Trends in the market: The MS drugs market in Croatia has been witnessing a shift towards newer disease-modifying therapies such as oral medications and monoclonal antibodies. This trend is driven by the increasing availability of these drugs in the market and their proven efficacy in treating MS. The market is also witnessing increased competition among drug manufacturers, leading to price reductions and better access to drugs for patients.
Local special circumstances: Croatia has a high prevalence of MS, with around 7,000 people suffering from the disease. The country has a well-established healthcare system that provides free healthcare to all citizens, including MS patients. The government has also implemented policies to improve access to MS drugs, including reimbursement schemes and drug price controls.
Underlying macroeconomic factors: Croatia's economy has been growing steadily in recent years, driven by tourism, manufacturing, and construction sectors. The country's accession to the European Union has also opened up new opportunities for trade and investment. These factors have contributed to the growth of the MS drugs market in Croatia, as patients have better access to healthcare and can afford to pay for expensive drugs.In conclusion, the MS drugs market in Croatia is expected to continue its growth trajectory in the coming years, driven by customer preferences, local special circumstances, and underlying macroeconomic factors. The market is likely to witness increased competition among drug manufacturers, leading to better access to drugs for patients. However, affordability and access to drugs remain a key concern, and the government needs to continue implementing policies to address these issues.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
